Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Yankees legend and Latin Grammy-nominee Bernie Williams and Multi-Platinum Recording Artist Jordin Sparks today debuted a new song, "Breath of Life...
Boehringer Ingelheim announced today that Carine Boustany, Ph.D., Global Head, Development Science + Head, Development Site U.S., has been appointed...
Boehringer Ingelheim today announced results from a phase III, randomized study that concluded that switching several times from Humira® (adalimumab) ...
Boehringer Ingelheim recently welcomed Yew Looi Liew (YL) as the newly appointed President of U.S. Human Pharma to its U.S. headquarters. Mr. Liew,...
Boehringer Ingelheim has entered a collaboration with the Yale Clinical and Translational Research Accelerator to launch a study exploring digital...
Boehringer Ingelheim today announced new data for Gilotrif® (afatinib) which further affirm its activity in squamous cell carcinoma of the lung and,...
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary...
Boehringer Ingelheim today announced the final analysis from GioTag, a real-world retrospective, observational study. The study assessed the impact...
Boehringer Ingelheim today announced a new analysis from the GioTag study, which showed that sequential Gilotrif® (afatinib) and osimertinib...
New York Yankees all-time great and Latin Grammy-nominee Bernie Williams is raising awareness of the disease that took his dad's life – idiopathic...
Boehringer Ingelheim announced today that Dr. Wolfgang Baiker, U.S. Country Managing Director, President and CEO, will retire after 31 years of...
Boehringer Ingelheim today presented results from a new retrospective analysis of real-world data that showed patients prescribed Spiriva® Respimat®...
Boehringer Ingelheim today announced the first patient enrolled in its Phase II clinical trial BALANCE-CF™ 1 to evaluate a new treatment for cystic...
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved Ofev® (nintedanib) as the first and only medicine to...
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative...
Boehringer Ingelheim and Optimum Patient Care today announced the creation of a new patient registry, APEX COPD (Advancing the Patient Experience in...
Boehringer Ingelheim today announced results from a phase III study, confirming that Cyltezo® is equivalent to Humira®*, with no clinically...
Boehringer Ingelheim Pharmaceuticals, Inc. today announced new presentations at the American Thoracic Society's 2018 annual conference that reinforce ...
Boehringer Ingelheim today announced that important sub-analyses from three major trials will be presented at the American College of Cardiology...
Boehringer Ingelheim today unveils "More Than Scleroderma™: The Inside Story," a new global initiative that highlights the importance of...
Boehringer Ingelheim today announced that their Phase II Alzheimer's disease trials with investigational compound BI 409306 had not met their...
A Boehringer Ingelheim survey of U.S. rheumatologists shows familiarity with biosimilars but a need for education. Contact: Boehringer Ingelheim...
Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and...
Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments...
A new documentary film, Clear the Air: Opening Up About COPD, which premiered today online, presents the compelling stories of three people who are...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.